Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006

Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop K-37, Atlanta, GA 30341-3724, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 11/2009; 302(19):2104-10. DOI: 10.1001/jama.2009.1672
Source: PubMed


Studies show that a large proportion of adults with high levels of low-density lipoprotein cholesterol (LDL-C) remain untreated or undertreated despite growing use of lipid-lowering medications.
To investigate trends in screening prevalence, use of cholesterol-lowering medications, and LDL-C levels across 4 study cycles (1999-2000, 2001-2002, 2003-2004, and 2005-2006).
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional, stratified, multistage probability sample survey of the US civilian, noninstitutionalized population. After we restricted the study sample to fasting participants aged 20 years or older (n = 8018) and excluded pregnant women (n = 464) and participants with missing data (n = 510), our study sample consisted of 7044 participants.
High LDL-C levels, defined as levels above the specific goal for each risk category outlined in guidelines from the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). All presented results are weighted and age-standardized to 2000 standard population estimates.
Prevalence of high LDL-C levels among persons aged 20 years or older decreased from 31.5% in 1999-2000 to 21.2% in 2005-2006 (P < .001 for linear trend) but varied by risk category. By the 2005-2006 study cycle, prevalence of high LDL-C was 58.9%, 30.2%, and 11.0% for high-, intermediate-, and low-risk categories, respectively. Self-reported use of lipid-lowering medications increased from 8.0% to 13.4% (P < .001 for linear trend), but screening rates did not change significantly, remaining less than 70% (P = .16 for linear trend) during the study periods.
Among the NHANES population aged 20 years or older, the prevalence of high LDL-C levels decreased from 1999-2000 to 2005-2006. In the most recent period, the prevalence was 21.2%.

Download full-text


Available from: Elena Kuklina, Oct 09, 2015
26 Reads
  • Source
    • "Large clinical studies showed that a significant population of adults is affected by hyperlipidaemia in the developed countries [1]. In the USA, approximately 100 million people (44.4%) suffered from hypercholesterolemia (>200 mg/dL) in 2008 [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although complex multivitamin products are widely used as dietary supplements to maintain health or as special medical food in certain diseases, the effects of these products were not investigated in hyperlipidemia which is a major risk factor for cardiovascular diseases. Therefore, here we investigated if a preparation developed for human use containing different vitamins, minerals and trace elements enriched with phytosterol (VMTP) affects the severity of experimental hyperlipidemia as well as myocardial ischemia/reperfusion injury. Male Wistar rats were fed a normal or cholesterol-enriched (2% cholesterol + 0.25% cholate) diet for 12 weeks to induce hyperlipidemia. From week 8, rats in both groups were fed with a VMTP preparation or placebo for 4 weeks. Serum triglyceride and cholesterol levels were measured at week 0, 8 and 12. At week 12, hearts were isolated, perfused according to Langendorff and subjected to a 30-min coronary occlusion followed by 120 min reperfusion to measure infarct size. At week 8, cholesterol-fed rats showed significantly higher serum cholesterol level as compared to normal animals, however, serum triglyceride level did not change. VMTP treatment significantly decreased serum cholesterol level in the hyperlipidemic group by week 12 without affecting triglyceride levels. However, VMTP did not show beneficial effect on infarct size. The inflammatory marker hs-CRP and the antioxidant uric acid were also not significantly different. This is the first demonstration that treatment of hyperlipidemic subjects with a VMTP preparation reduces serum cholesterol, the major risk factor for cardiovascular disease; however, it does not provide cardioprotection.
    Lipids in Health and Disease 09/2013; 12(1):138. DOI:10.1186/1476-511X-12-138 · 2.22 Impact Factor
  • Source
    • "This work confirms poor adherence to NCEP guidelines for managing elevated levels of LDL-cholesterol.9–16 van Wyk et al27 have shown, in this regard, that electronic alerts keyed to data in an electronic medical record can improve adherence to the guidelines. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Validated guidelines to manage low-density lipoprotein (LDL)-cholesterol are utilized inconsistently or not at all even though their application lowers the incidence of coronary events. New approaches are needed, therefore, to implement these guidelines in everyday practice. We compared an automated method for applying The National Cholesterol Education Panel (NCEP) guidelines with results from routine care for managing LDL-cholesterol. The automated method comprised computerized history-taking and analysis of historical data without physician input. Results from routine care were determined for 213 unselected patients and compared with results from interviews of the same 213 patients by a computerized history-taking program. Data extracted from hospital charts showed that routine care typically did not collect sufficient information to stratify risk and assign treatment targets for LDL-cholesterol and that there were inconsistencies in identifying patients with normal or elevated levels of LDL-cholesterol in relation to risk. The computerized interview program outperformed routine care in collecting historical data relevant to stratifying risk, assigning treatment targets, and clarifying the presence of hypercholesterolemia relative to risk. Computerized history-taking coupled with automated analysis of the clinical data can outperform routine medical care in applying NCEP guidelines for stratifying risk and identifying patients with hypercholesterolemia in relation to risk.
    Vascular Health and Risk Management 11/2010; 6(1):1039-46. DOI:10.2147/VHRM.S14302
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objetivo. Describir las tendencias en la prevalencia de diabetes tipo 2 (T2D), y otros factores de riesgo cardiovascular como las dislipidemias y la hipertensión en tres encuestas nacionales de salud (1993, 2000 y 2006). Material y Métodos. Las bases de datos de ENEC 1993, ENSA 2000 y ENSANUT 2006 fueron reprocesados para asegurar la comparabilidad entre las encuestas. Resultados. Entre 1993 y 2006 la prevalencia de T2D (6.7-14.4%), síndrome metabólico (26.6-36.8%), hipertensión (23.8-30.7%), hipercolesterolemia (27-43.6%), y LDL-colesterol alto (31.6-46%) aumentaron rápidamente. La prevalencia de concentraciones bajas de HDL-colesterol fue muy alta (60.5-63%) en todas las encuestas, manteniéndose esencialmente sin cambios. Conclusión. La tendencias crecientes en las prevalencias de T2D y factores de riesgo cardiovascular predicen que a corto plazo habrá importantes incrementos en la morbilidad y mortalidad asociada a la T2D y enfermedades cardiovasculares, por lo que deben intensificarse las estrategias para prevenir y reducir los incrementos dramáticos previstos en la carga de enfermedad
    Salud publica de Mexico 01/2010; 52(1). · 0.94 Impact Factor
Show more